- Menachem R, Nudelman I, Vorontsova A, Livneh I, Sela M, Benguigui M, Manobla B, Shammai Y, Deo A, Buxbaum C , Bessler R, Raviv Z , Shklover J, Sznitman J, , Ciechanover A, Schroeder A, Shaked Y. Bone Marrow-Targeted Liposomes Loaded with Bortezomib Overcome Multiple Myeloma Resistance. ACS Nano. 2025 Mar 21.
- Benguigui M*, Cooper TJ* , Kalkar P , Schif-Zuck S, Halaban R, Bacchiocchi A, Kamer I, Deo A, Manobla B, Menachem R, Haj-Shomaly J, Vorontsova V, Raviv Z, Buxbaum B, Christopoulos P, Bar J, Lotem M, Sznol M, Ariel A, Shen-Orr S, Shaked Y. Interferon-stimulated neutrophils as a predictor of immunotherapy response. Cancer Cell. 2024 Feb 12;42(2):253-265.
- Deo A, Sleeman J, Shaked Y. The role of host response to chemotherapy: resistance, metastasis and clinical implications. Clin Exp Metastasis. 2023 Nov 24: 10585-023-10243-5.
- Vorontsova A., Cooper TJ., Haj-Shomaly J., Benguigui M., Levin S., Manobla B., Menachem R., Timaner M., Raviv Z., Shaked Y. Chemotherapy-induced tumor immunogenicity is mediated in part by megakaryocyte-erythroid progenitors. Oncogene. 2023 Mar;42(10):771-781.
- Udasin, R., Sil, A., Zomot, E., Achildiev Cohen, H., Haj, J., Engelmayer, N., Lev, S., Binshtok, AM., Shaked, Y., Kienzler, MA., and Palty, R. Photopharmacological modulation of native CRAC channels using azoboronate photoswitches. PNAS 2022 Mar 29;119(13).
- Waldhom, I., Holland, R., Goshen-Lago, T., Benguigui, M., Halberthal, M., Shaked, Y., Ben-Aharon, I., Long-term immunogenicity of BNT162b2 vaccine in patents with solid tumors. JAMA Oncology, 2022;8(6):940-941.
- Harel, M., Lahav, C., Jacob, E., Dahan, N., Sela, I., Elon, Y., Raveh Shoval S., Yahalom, G., Kamer, I., Zer, A., Sharon, O., Carbone, D., Dicker, A., Bar, J., and Shaked Y. Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade. Journal of immunotherapy of cancer 2022;10:e004582.
- Benguigui, M., Vorontsova, A., Timaner, M., Levin, S., Haj-Shomaly, J., Deo, A., Menachem, R., Manobla, B., Cooper, TJ., Raviv, Z., Shaked, Y. Bv8 blockade sensitizes anti-PD1 therapy resistant tumors. Frontiers in immunology 07 July 2022.
- Haj-Shomaly J, Vorontsova A, Barenholz-Cohen T, Levi-Galibov O, Devarasetty M, Timaner M, Raviv Z, Cooper T, Soker S, Hasson P, Weihs D, Scherz-Shouval R, Shaked Y. T cells promote metastasis by regulating extracellular matrix remodeling following chemotherapy. Cancer Res 2022 Jan 15 (cover and editorial).
- Khononov, I., Jacob, E., Fremder, R., Dahan, D., Harel, M., Raviv, Z., Krastev, B., Shaked, Y. Host response to immune checkpoint inhibitors contributes to tumor aggressiveness. Journal of Immunotherapy of Cancer 2021; 9(3):e001996.
- Magidey-Klein, K., Cooper, TJ., Kveler, K., Normand, R., Zhang, T., Timaner, M., Raviv, Z., James, BP., Gazit, R., Ronai, ZA., Shen-Orr, S., Shaked, Y. IL-6 contributes to metastatic switch via the differentiation of monocytic-dendritic progenitors into prometastatic immune cells. Journal of Immunotherapy of Cancer 2021; 9(6):e002856.
- Bondarenko, M., Le Grand, M., Shaked Y., Raviv Z., Chapuisat, G., Carrere C., Montero, MP., Rossi, M., Pasquier, E., Carre, M., Andre, N. Metronomic chemotherapy modulates clonal interactions to prevent drug resistance in non-small cell lung cancer. Cancers 2021; 13(9):2239.
- Wadhorn, I., Holland, R., Goshen-Lago, T., Shirman, Y., Szwarcwort-Cohen, M., Reiner-Benaim, A., Shachor-Meyouhas, Y., Hossein, K., Fahoum, L., Peer A., Almong, R., Shaked Y., Halberthal, M., Ben-Aharon, I. Six Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors. Cancer Discovery 2021: 11(10): 2430–2435.
- Timaner, M#., Kotsofruk, R.#, Raviv, Z., Magidey, K., Shechter, D., Kan, T., Nevelsky, A., Daniel, S., de Vries, EGD, Zhang, T., Kaidar-Person, O., Kerbel, RS., Shaked, Y. Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1. Oncogene 2020; 39(1):187-203. [# equal contribution].
- Bhattacharya, U., Gutter-Kapon, L., Kan, T., Boyango, I., Barash, U., Yang, S., Liu, J., Gross-Cohen, M., Sanderson, RD., Shaked, Y., Ilan, N. and Vlodavsky, I. Heparanase and chemotherapy synergize to drive macrophage activation and enhance tumor growth. Cancer Research 2020; 80(1):57-68.
- Avraham, S., Abu-Sharqi, S., Shofti, R., Haas, T., Korin, B., Kalfon, R., Shaked, Y*., and Aronheim A.* Early Cardiac Remodeling Promotes Tumor Growth and Metastasis. Circulation 2020; 42(7):670-683. [*equal contribution].
- Zhang, GL., Gutter-Kapon, L., Ilan, N., Batool, T., Singh, K., Digre, A., Luo, Z., Sandler, S., Y., Sanderson, RD., Wang, X., Li, J., and Vlodavsky, I. Significance of host heparanase in promoting tumor growth and metastasis. Matrix Biology 2020;S0945-053X(20)30066-4.
- Shechter D., Harel M., Mukherjee, A., Sagredo LM., Loven, D., Prinz, E., Avraham, S., Orian-Rousseau V., Geiger, T., Shaked Y.*, Wolfenson H.* Breast cancer derived microparticles reduce cancer cell adhesion, an effect augmented by chemotherapy. Cells 2020; 9(10): 2269 [equal contribution and co-corresponding].
- Kan, T., Feldman, E., Timaner, M., Raviv, Z., Shen-Orr, SS., Aronheim, A.*, , Shaked Y.* IL-31 induces anti-tumor immunity in breast carcinoma. Journal of Immunotherapy of Cancer 2020 Aug;8(2):e001010. [*equal contribution].
- Khan, KA., Ponce de Léon, JL., Benguigui, M., Xu, P., Chow, A., Cruz-Muñoz, W., Man, S., Shaked, Y., Kerbel, RS. Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer. NPJ Breast Cancer 2020; 20; 6:29.
- Barenholz-Cohen, T., Merkher, Y., Haj, J., Shechter, D., Kirchmeier, D., Shaked, Y., Weihs, D. Lung mechanics modifications facilitating metastasis are mediated in part by breast cancer derived extracellular vesicles. International J. Cancer 2020; 147(10):2924-2933.
- Goshen-Lago, T., Szwarcwort-Cohen, M., Benguigui, M., Almog, R., Turgeman, I., Zaltzman, N., Halberthal, M., Shaked, Y*., Ben-Aharon, I.* The Potential Role of Immune Alteration in the Cancer–COVID19 Equation—A Prospective Longitudinal Study. Cancers 2020; 12(9):2421. [*equal contribution].
- Timaner, M., Tsai, K., and Shaked Y. The multifaceted role of mesenchymal stem cells in cancer. Seminars in Cancer Biology 60; 225-237.
- Vorontsova, A., Kan, T., Raviv, Z., and Shaked, Y. The Dichotomous Role of Bone Marrow Derived Cells in the Chemotherapy-Treated Tumor Microenvironment. J Clinical Medicine 2020; 9(12):3912.
- Avraham, S., Korin, B., Aviram S., Shechter, D., Shaked Y.,* Areonheim A*. ATF3 and JDP2 deficiency in cancer associated fibroblasts promotes tumor growth via SDF-1 transcription. Oncogene 2019; 38(20):3812-3823. [*equal contribution].
- Beyar-Katz, O., Magidey, K., Reiner-Benaim, A., Barak, N., Avivi, I., Cohen, Y., Timaner, M., Avraham, S., Hayun, M., Lavi, N., Bersudsky, M., Voronov, E., Apte, RN., Shaked, Y. Pro-inflammatory macrophages promote multiple myeloma resistance to bortezomib therapy. Molecular Cancer Research 2019;17(11):2331-2340.
- Benguigui, M., Weitz, SI., Timaner, M., Kan, T., Shechter, D., Perlman, O., Sivan, S., Raviv, Azhari, H., Shaked, Y. Copper oxide nanoparticles inhibit pancreatic tumor growth primarily by targeting tumor initiating cells. Scientific Report 2019; 9(1):12613.
- Tsai, K., Chan, TS., and Shaked Y. Next viable routes to targeting pancreatic cancer stemness: learning from clinical setbacks. Journal of Clinical Medicine 2019;8(5).
- Chan, TS., Shaked, Y., Tsai, KK. Targeting the Interplay Between Cancer Fibroblasts, Mesenchymal Stem Cells, and Cancer Stem Cells in Desmoplastic Cancers. Frontiers Oncology 2019;9:688.
- Shaked, Y. The pro-tumorigenic host response to cancer therapy. Nature Reviews Cancer 2019(12):667-685.
- Timaner, M., Letko-Khait, N., Kotsofruk, R., Benguigui, M., Beyar-Katz, O., Rachman-Tzemach, C., Raviv, Z., Bronshtein, T., Machluf, M., and Shaked, Y. Therapy-educated mesenchymal stem cells enrich for tumor initiating cells. Cancer Research 2018;78(5):1253-1265.
- Perlman, O., Weitzb, IS., Sivanb, SS., Abu-Khallab, H., Benguigui, M., Shaked, Y., and H. Azharia. Copper oxide loaded PLGA nanospheres: Towards a multifunctional nanoscale platform for ultrasound based imaging and therapy. Nanotechnology 2018; 29(18):185102.
- Gutter-Kapon, L., Alishekevitz, D., Shaked, Y., Li, JP., Aronheim, A., Ilan, N., and Vlodavsky, I. Heparanase is required for activation and function of macrophages. PNAS 2017; 29;113(48):E7808-E7817.
- Davidi, D.*, Fremder, E.*, Kan, T., Raviv, Z., Timaner, M., Karin, N., Hershkovitz, D., Arohneim, A.,# and Shaked, Y.# The antiangiogenic role of the pro-inflammatory cytokine interleukin-31. Oncotarget 2017; 8(10):16430–16444. [*,# equal contribution].
- Rachman-Tzemah C., Zaffryar-Eilot S., Grossman M., Ribero D., Timaner M., Mäki JM, Myllyharju J., Bertolini F., Hershkovitz D., Sagi I., Hasson P., and Shaked Y. Blocking Surgically Induced Lysyl Oxidase Activity Reduces the Risk of Lung Metastases. Cell Reports 2017;19(4):774-784.
- Hawila, E., Razon, H., Wildbaum, G., Blattner, C., Sapir, Y., Shaked, Y., Umansky, V. and Karin, N. CCR5 directs the mobilization of CD11b+Gr1+Ly6Clow polymorphonuclear myeloid cells from the bone marrow to the blood to support tumor development. Cell Reports 2017;21;21(8):2212-2222.
- Benguigui, M., Alishekevitz, D., Timaner, M., Shechter, D., Raviv, Z., Benzekry, S.* and Shaked, Y.*. Dose- and time-dependence of the host-mediated response to paclitaxel therapy: a mathematical modeling approach. Oncotarget 2017; 9(2):2574-2590 [* equal contribution].
- Kerbel, RS. and Shaked Y. The potential clinical promise of multimodality metronomic chemotherapy revealed by preclinical studies of metastatic disease. Cancer Letters 2017; 1;400:293-304.
- Timaner, M., Beyar-Katz, O., and Shaked, Y. Analysis of the stromal cellular components of the solid tumor microenvironment using flow cytometry. Current Protocols – Cell Biology. 2016 1;70:19.18.1-19.18.12.
- Tiram, G., Segal, E., Krivitsky, A., Shreberk-Hassidim, R., Ofek, P., Ferber, S., Udagawa, T., Edry, L., Shomron, N., Roniger, M., Kerem, B., Shaked, Y., Aviel-Ronen, S., Barshack, I., Calderon, M., Haag, R., and Satchi-Fainaro, R. Identification of Dormancy-Associated MicroRNAs for the Design of Osteosarcoma-Targeted Dendritic Polyglycerol Nanopolyplexes. ACS-nano 2016;10(2):2028-45.
- Beyar-Katz, O., Magideym K. Ben-Tsedek, N., Alishekevitz, D., Timaner, M., Miller, V., Lindzen, M., Yarden, Y., Avivi, I., and Shaked, Y. Bortezomib-induced pro-inflammatory macrophages contributes to multiple myeloma cell aggressiveness Journal of Pathology. 2016 239(3):262-73. (Editorial in the same journal).
- Shaked, Y.*, Pham, E., Hariharan S., Beyar-Katz, O., Xu, P., Man, S., Wu, F., Miller, V., Magidey, K., Andrews, D., Kerbel, RS. High-throughput systems analyses of host and tumor responses to maximum tolerated dose or metronomic low-dose capecitabine chemotherapy. Cancer Research. 2016, 76(20):5983-5993. [* co-corresponding authors]
- Alishekevitz, D., Gingis-Velitski, S., Kaidar-Person, O., Gutter-Kapon, L., Klusmeier, S., Merquiol, E., Ben-Nun, Y., Miller, V., Rachman-Tzemah, C., Timaner, M., Mumblat, Y., Raviv, Z., Ilan, N., Loven, D., Satchi-Fainaro, R., Blum, G., Sleeman, J., Vlodavsky, I., and Shaked, Y. Macrophage-induced lymphangiogenesis and metastasis following paclitaxel chemotherapy is regulated by VEGFR3. Cell Reports 2016; 17(5):1344-1356.
- Shaked, Y. Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. Nature Reviews Clin. 2016; 13(10):611-26.
- Pantziarka, P., Hutchinson, L., André, N., Benzekry, S., Bertolini, F., Bhattacharjee, A., Chiplunkar, S., Duda, DG., Gota, V., Gupta, S., Joshi, A., Kannan, S., Kerbel, RS., Kieran, M., Palazzo, A., Parikh, A., Pasquier, E., Patil, V., Prabhash, K., Shaked, Y., Saulnier-Sholler, S., Štěrba, J., Waxman DJ. and Banavali, S. Next generation metronomic chemotherapy—report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6–8 May 2016, Mumbai. e-cancer medical sciences. 2016;10:689.
- Harel, M., Oren-Giladi, P., Kaidar-Person, O., Shaked, Y., and Geiger, T. PROMIS-Quan: a novel proteomic method for plasma biomarker quantification. Molecular and Cellular Proteomics 2015;14(4):1127-36.
- Voloshin, T., Alishekevitz, D., Kaneti, L., Miller, V., Isakov, E., Kaplanov, I., Voronov, E., Benhar, M., Machluf, M., Apte, RN., and Shaked, Y. Blocking IL-1β pathway following paclitaxel chemotherapy slightly inhibits primary tumor growth but promotes spontaneous metastasis. Molecular Cancer Therapeutics 2015;14(6):1385-94.
- Schaffer, M., Bril, R., Batash, R., Ehernberg, B., Leshem, G., Rahimipour, S., and Shaked, Y. Hypericin and its derivatives act as radiosensitizing agents that can inhibit tumor initiating cell viability. Clinical Cancer Drugs 2015; 2(2): 119–127.
- Timaner, M.,* Bril, R.,* Kaidar-Person, O., Rachman, R., Alishekevitz, D., Kotsofruk, R., Miller, V., Nevelsky, A., Daniel, S., Raviv, Z., Rotenberg SA., and Shaked, Y. Dequalinium blocks macrophage-induced metastasis following local radiation. Oncotarget 2015; 29;6(29):27537-54.[* equal contribution]
- Koren, L., Alishekevitz, D., Elhanani, O1., Nevelsky, A., Hai, T., Kehat, I., Shaked, Y., and Aronheim, A. ATF3-dependent cross-talk between cardiomyocytes and macrophages promotes cardiac maladaptive remodeling. International Journal of Cardiology 2015;1;198:232-40.
- Barbarov, Y., Timaner, M., Alishekevitz, D., Hai, T., Yokoyama, KK., Shaked, Y.,* and Aronheim, A*. Host JDP2 expression in the bone marrow contributes to metastatic spread. Oncotarget 2015;6(35):37737-49. [* equal contribution]
- Beyar-Katz, O. and Shaked, Y. Host effects contributing to cancer therapy resistance. Drug Resistance Updates 2015; 19:33-42
- Alishekevitz, D., Bril, R., Loven, D., Miller, V., Voloshin, T., Gingis-Velistki, S., Fremder, E., Scherer, SJ and Shaked, Y. Differential therapeutic effects of anti-VEGF-A antibody in different tumor models: implications for choosing appropriate tumor models for drug testing. Molecular Cancer Therapeutics. 2014; 13(1):202-13.
- Fremder, E.*, Munster, M.*, Aharon, A., Miller, V., Gingis-Velitski, S., Voloshin, T., Alishekevitz, D., Bril, R., Scherer, SJ., Loven, D., Brenner, B., Shaked, Y. Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: a process regulated by osteopontin. International Journal of Cancer. 2014; 135(2):270-81. [* equal contribution]
- Buckstein, R., Kerbel, RS., Cheung, M., Shaked, Y., Chodirker, L., Lee, C., Davidson, C., Lenis, M., Cussen, M., Reis, M., Chesney, A., Zhang, L., Wells, R. Lenalidomide and metronomic melphalan for CMML and higher risk MDS: A phase 2 clinical study with biomarkers of angiogenesis. Leukemia Research 2014; 38(7):756-63.
- Munster, M.*, Fremder, E.*, Miller, V., Ben-Tsedek, N., Scherer, SJ., Shaked, Y. Anti-VEGF-A alters the angiogenic properties of tumor derived microparticles. Plos One 2014; 21;9(4):e95983. [* equal contribution].
- Hasnis, E., Alishekevitz, D., Gingis-Veltski, S., Bril, R., Alishekevitz D., Fremder, E., Voloshin, T., Raviv, Z., Karban, A., and Shaked, Y., Both anti-Bv8 antibody and metronomic gemcitabine improve outcome of pancreatic adenocarcinoma following treatment with weekly gemcitabine. Neoplasia 2014, 16(6):501-10.
- Daenen, LGM., Roodhart, JML., Shaked, Y. and Voest, EE. Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies. Oncogene 2014; 33(11):1341-7.
- Shaked, Y., McAllister, S., Fainaru, O. and Almog, N. Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow-Derived Cells. Current Pharmacological design 2014; 20(30):4920-33.
- Voloshin, T., Fremder, E. and Shaked, Y. Small but mighty: microparticles as mediators of tumor progression. Cancer Microenvironment 2014; 7(1-2):11-21.
- Bouche, G., André, N., Banavali, S., Berthold, F., Berruti, A., Bocci, G., Brandi, G., Cavallaro, U., Cinieri, S., Colleoni, M., Curigliano, G., Desidero, TD., Eniu, A., Fazio, N., Kerbel, R., Hutchinson, L., Ledzewicz, U., Munzone, E., Pasquier, E., Graciela Scharovsky, O., Shaked, Y., Stěrba, J., Villalba, M., Bertolini, F. Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. e-cancer medical sciences. 2014; 8:463.
- Benayoun, L., Schaffer, M., Bril, R., Gingis-Velitski, S., Segal, E., Nevelsky A., Satchi-Fainaro, R. and Shaked, Y. Porfimer-sodium (Photofrin-II) in combination with ionizing radiation inhibits tumor initiating cell proliferation and improves glioblastoma treatment efficacy. Cancer Biology and Therapy 2013;14(1):64-74. (Cover).
- Benayoun, L., and Shaked, Y. In vitro Enrichment of Tumor Initiating Cells from Human Established Cell Lines. Current Protocols – Stem Cell Biology. 2013; Unit3.7.
- Miller, K., Clementi, C., Polyak, D., Eldar-Boock, A., Benayoun, L., Barshack, I., Shaked, Y., Pasut, G., and Satchi-Fainaro, R. Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases Biomaterials 2013; 34(15):3795-806.
- Zaffryar-Eilot, S., Marshall, D., Voloshin, T., Bar-Zion, A., Spangler, R., Kessler, O., Ghermazien, H., Brekhman, V., Suss-Toby, E., Adam, D., Shaked, Y., Smith, V., Neufeld, GA. Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours. Carcinogenesis 2013; 34(10):2370-9.
- Loven, D., Hasnis, E., Bertolini, F. and Shaked, Y. Low-Dose Metronomic Chemotherapy: from Past Experience to New Paradigms in the Treatment of Cancer. Drug Discovery Today. 2013;18(3-4):193-201.
- Voloshin, T., Voest, EE. And Shaked, Y. The host immunological response to cancer therapy: an emerging concept in tumor biology. Experimental Cell Research 2013, S0014-4827(13)00115-8.(Cover).
- Izhak, L., Wildbaum, G., Jung, S., Stein, A., Shaked, Y., and Karin, N. Dissecting the autocrine and paracrine roles of the CCR2-CCL2 axis in tumor survival and angiogenesis. PLoSONE, 2012;7(1):e28305. [Correction in: 2018 Apr 12;13(4):e0195170].
- Francia, G, Shaked, Y, Hashimoto, K, Sun, J, Yin, M, Cesta, C, Xu, P, Man, S, Hackl, C, Stewart, J, Uhlik, M, Dantzig, AH, Foster, S, Kerbel, RS. Low-dose metronomic oral dosing of a prodrug of Gemcitabine (LY2334737) causes anti-tumor effects in the absence of inhibition of systemic vasculogenesis. Molecular Cancer Therapeutics 2012; 11(3):680-9.
- Bertolini, F., Mancuso, P., Benayoun, L., Gingis-Velitski, S. and Shaked Y. Chemotherapy-induced circulating bone marrow derived endothelial progenitor cell mobilization in cancer patients. Methods Molecular Biology. 2012;904:165-72.
- Benayoun, L., Gingis-Velitski, S., Voloshin, T., Segal, E., Segev, R., Munster, M., Bril, R., Satchi-Fainaro, R., Scherer, SJ., and Shaked, Y. Tumor initiating cells of various tumor types exhibit differential angiogenic properties and react differently to antiangiogenic drugs. Stem Cells 2012; 30(9):1831-41.
- Emmenegger, U., Francia, G., Chow, A., Shaked, Y., Kouri, A., Man, S., Kerbel, RS. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 2011; 13(1):40-8.
- Segal, E., Pan, H., Benayoun, L., Kopecková, P., Shaked, Y., Kopecek, J., and Satchi-Fainaro, R. Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances. Biomaterials 2011, 32(19): 4450-63.
- Miller, K., Elday-Boock, A., Polyak, D., Segal, E., Benayoun, L., Shaked, Y., and Satchi-Fainaro, R. Anti-angiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastases mouse model. Molecular pharmacology. 2011;8(4):1052-62.
- Voloshin, T., Gingis-Veltski, S., Milsom, C., Man, S., Munster, M., Kerbel, RS., and Shaked, Y. G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist. Blood 2011; 118(12):3426-35.
- Schmid, MC., Avraamides, DJ., Foubert, P., Shaked, Y., Kang, SW., Kerbel, RS., and Varner, JA. Combined blockade of integrin α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth. Cancer Research 2011; 71(22):6965-75.
- Gingis-Velitski, S., Loven D., Benayoun, L., Munster, M., Bril, R., Voloshin, T., Alishekevitz, D., Bertolini, F. and Shaked, Y. Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. Cancer Research. 2011; 71(22):6986-96. (Editorial in SciBX journal NOV2011).
- Bertolini, F., Marighetti, P., Martin-Padura, I., Mancuso, P., Hu-Lowe, D., Shaked, Y., and D’Onofrio, A. Anti-VEGF and beyond: Shaping a new generation of anti-angiogenic therapies for cancer. Drug Discovery Today 2011;16(23-24).
- Pasquier, E., Kieran, M.W., Sterba, J., Shaked, Y., Baruchel, S., Oberlin, O., Kivivuori, M.S., Peyrl, A., Diawarra, M., Casanova, M., Zacharoulis, S., Vassal, G., Berthold, F., Verschuur, A. and Andre, N. Moving forward with metronomic scheduling of anti-cancer treatment: meeting report of the 2nd international workshop on metronomic and anti-angiogenic chemotherapy in paediatric oncology. Translational Oncology. 2011; 4(4):203-11).
- Izhak, L., Wildbaum, G., Weinberg U., Shaked, Y., Alami, J., Dumont, D., Stein, A., and Karin, N. Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner. Immunology. 2010 15;184(2):1092-101. [Correction in: 2018 Apr 1;200(7):2509-2510]
- Langenberg, MHG., Nijkamp, MW., Roodhart, JML., Snoeren, N., Shaked, Y., van Hillegersberg, R., Witteveen, PO., Vermaat, JSP., Kranenburg, O., Kerbel, RS., Medema, RH., Borel Rinkes, IHM., and Voest, EE. Liver surgery induces an immediate mobilization of (endothelial) progenitor cells in liver cancer patients. Cancer Biology and Therapy. 2010;18;9(9).
- Emmenegger, U., Francia, G., Shaked, Y. and Kerbel, RS. Metronomic Chemotherapy - Principles and Lessons Learned from Applications in the Treatment of Metastatic Prostate Cancer. Recent Results Cancer Research. 2010;180:165-83.
- Daenen, LG., Roodhart, JM., Shaked, Y., and Voest, EE. Vascular disrupting agents (VDAs) in anticancer therapy. Current Clinical Pharmacology. 2010; 5; 178-185.
- Bertolini, F., Marighetti, P., and Shaked, Y. Cellular and soluble markers of tumor angiogenesis: from patient selection to the identification of the most appropriate post-resistance therapy. BBA reviews on Cancer 2010; 1806(2):131-7.
- Calleri, A.,Bono, A.,Quarna, J.,Mancuso, P., Rabascio, C., Bagnardi, V., Shaked, Y., Goldhirsch, A., Colleoni,M. and Bertolini, F. Long-term patterns and predictive potential of angiogenic growth factors and circulating endothelial cells in advanced breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clinical Cancer Research 2009;15(24):7652-7657.
- Shaked, Y.‡, Tang, T., Woloszynek, J., Daenen, LG., Man, S., Xu, P., Cai, SR., Wong, J., Arbeit, J., Varner, J., Voest, EE., Chaplin, C., Smythe, J., Harris, A., Nathan, P., Judson, I., Rustin, G., Bertolini, F., Link, D. and Kerbel RS.‡ Contribution of G-CSF to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Research. 2009;69(19):7524-8. [‡ corresponding authors].
- Folkins, C., Shaked, Y., Man, S., Tang, T., Lee, CR., Hoffman, RM, and Kerbel, RS. Glioma tumor stem-like cells promote tumor angiogenesis via VEGF- and SDF1-mediated promotion of endothelial cell activity and recruitment of bone marrow-derived endothelial progenitor cells. Cancer Research 2009;69(18):7243-51.
- Daenen LG, Shaked, Y.‡, Man, S., Xu, P., Voest, EE., Hoffman, RM., and Kerbel, RS. Combining Metronomic Chemotherapy with Vascular Disrupting Agent (VDA) Therapy: Impact on Primary Breast Tumors versus Advanced Metastatic Disease. Molecular Cancer Therapeutics 2009 ;8(10):2872-81.[‡ corresponding author].
- Bertolini, F., Mancuso, P., Braidotti, Shaked, Y., Kerbel, R.S. The multiple personality disorder of circulating endothelial cells in cancer. BBA reviews on Cancer, 2009;1796(1):27-32.
- Shaked, Y.‡ and Voest EE‡. Bone marrow derived cells in tumor angiogenesis and growth: are they the good, the bad, or the evil? BBA reviews on Cancer 2009;1796(1):1-4. [‡corresponding authors].
- Donate, F., Parry G.C., Shaked, Y., Hensley, H., Guan, X., Beck, I., Tel-Tsur, Z., Plunkett, ML., Shaw, DE., Kerbel, RS and Mazar, AP. Pharmacology of the novel anti-angiogenic peptide, ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose response in several preclinical models of angiogenesis and tumor growth. Clinical Cancer Research. 2008; 14(7):2137-44.
- Francia, G., Emmenegger, U., Lee CR., Shaked, Y., Folkins, C., Mossoba, M., Jeffrey, AM., Man, S. and Kerbel, RS. Long term monitoring of metastasis models using a transfected marker detectable in the mouse urine. Molecular Cancer Therapeutics. 2008; 7(10):3452.
- Voskas, D., Babichev, Y., Ling, LS., Alami, J., Shaked, Y., Kerbel RS and Dumont DJ. An eosinophil-specific cytokine and chemokine profile characterizes the inflammatory skin disease observed in Tie-2 transgenic mice. Leukocyte Biology. 2008;84(1):59-67.
- Shaked, Y.‡, Henke, E., Roodhart, J., Mancuso, P., Langenberg, M., Colleoni, M., Daenen, LG., Man, S., Xu, P., Emmenegger, U., Tang, T., Zhu, Z., Witte, L., Strieter, RM., Bertolini, F., Voest, EE., Benezra, R. and Kerbel RS.‡, Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell. 2008;14(3):263-73. (Editorial in the same issue of Cancer Cell). [‡ corresponding authors].
- Glade-Bender, JL., Adamson, PC., Reid, JM., Xu, L., Baruchel, S., Shaked, Y., Kerbel, RS., Cooney, E., Stempak, D., Chen, HX., Nelson, MD., Krailo, MD., Ingle, AM., Blaney, SM., Kandel, JJ. and Yamashiro, DJ. “Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A Children’s Oncology Group Study. Clinical Oncology. 2008; 26(3):399-405.
- Dellapasqua S., Bertolini, F., Bagnardi, V., Campagnoli, E., Scarano, E., Torrisi, R., Shaked, Y., Mancuso, P., Goldhirsch, A., Rocca, A., Pietri, E. and Colleoni, M. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer: clinical and biological activity. Clinical Oncology. 2008;26(30):4899-905.
- Loven, D., Be’ery, E., Yeryshaimi, R., Koren, C., Sulkes, A., Lavi, I., Shaked, Y., Fenig, E. Daily low-dose/continuous capecitabine reduces VEGF and PDGF-BB serum levels in rectal carcinoma patients receiving neoadjuvant irradiation. Acta Oncologica. 2007 :1-6.
- Cervi, D.*, Shaked, Y.*, Haeri, M.*, Usenko, T. Lee, C.R., Nagy, A., Kerbel R.S., Yefenof, E., Ben-David, Y. Enhanced Natural Killing and Erythropoietic Activity in VEGF Overexpressing Mice Delays F-MuLV Induced Leukemogenesis. Blood 2007;109(5):2139-46 [* equal contribution].
- Folkins, C., Man, S., Xu, P., Shaked, Y., Hicklin, DJ. and Kerbel, R.S. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Research 2007; 67(8):3560-4.
- Emmenegger, U.*, Shaked, Y.*, Bocci, G., Spasojevic, I., Ludeman, S., Man, S. and Kerbel, R.S. Altered metabolism of cyclophosphamide given in a low-dose metronomic manner does not account for eventual resistance. Molecular Cancer Therapeutics. 2007; 6(8):2280-9. [* equal contribution].
- Bosch-Marce, M., Okuyama, H., Kimura, H., Wesley, J., Sarkar, K., Liu, YV., Zhang, H., Strazza, M., Savino, L., Zhou, YF., Rainey, K., Na, Y., Vandiver, S., Rabi, A., Shaked, Y., Kerbel, RS., La Vallee, T., Sugar, E. and Semenza, GL. Effects of aging and HIF-1 activity on angiogenic cell mobilization and recovery of perfusion following critical limb ischemia. Circulation Research, 2007;101(12):1310-8.
- Ciarrocchi, A.*, Jankovic, V.*, Shaked, Y., Nolan, DJ., Mittal, V., Kerbel RS., Nimer SD. and Benezra R. Id1 controls an angiogenic switch in the bone marrow by inhibiting the expression of p21. 2007;2(12):e1338 [* equal contribution].
- Shaked, Y. and Kerbel RS. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Research. 2007; 67(15):7055-8.
- Bertolini, F., Mancuso, P., Shaked, Y., Kerbel, R.S. Molecular and cellular biomarkers of angiogenesis in oncology. Drug Discovery Today. 2007; 12(19-20):806-12.
- Emmenegger, U., Morton, G.C., Francia, G., Shaked, Y., Franco, M., Man, S. and Kerbel, R.S. Low-dose metronomic cyclophosphamide induces sustained hypoxia in human tumor xenografts, which can be exploited therapeutically by the combination with the hypoxic cell cytotoxin tirapazamine. Cancer Research, 2006; 66:1664-74 (Commentary in Cancer Research Highlights of the same issue).
- Franco, M., Man, S., Chen, L., Emmenegger, U., Shaked, Y., Cheung, A., Brown, A., Hicklin, DJ., Foster, S. and Kerbel, RS. Targeted Antiangiogenic Therapy Leads to Short and Long Term Impairment of Vascular Function and Increases in Tumor Hypoxia. Cancer Research. 2006;66(7):3639-48.
- Munoz, R., Man, S., Shaked, Y., Lee CR., Wong, J., Francia, G., Kerbel, RS. Highly efficacious non-toxic preclinical treatment for advanced metastatic breast cancer using oral combination UFT-Cyclophosphamide metronomic chemotherapy. Cancer Research. 2006;66(7):3386-91.
- Mancuso, R., Colleoni, M., Calleri, A., Orlando, L., Maisonneuve, P., Pruneri, G., Agliano, A., Goldhirsch, A., Shaked, Y., Kerbel, R.S., and Bertolini, F. Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006; 108(2):452-9. (Commentary in Nature Reviews Cancer (May 2006), and Editorial in the same issue of Blood).
- Ng, S., Sparreboom, A., Shaked, Y., Lee, RC., Man, S., Desai, N., Soon-Shiong, P., Figg, W. and Kerbel, R.S. Metronomic ABI-007 Therapy: Antiangiogenic and Antitumor Activity of a Nanoparticle Albumin-bound Paclitaxel. Clinical Cancer Research. 2006; 12(14):4331-8.
- Shaked, Y.*, Ciarrocchi, A*., Franco, M., Lee, C.R., Man, S., Cheung, A., Hicklin DJ., Chaplin, D., Foster, SF, Benezra, R., Kerbel RS. Therapy-induced Recruitment of Circulating Endothelial Progenitor Cells to Tumors. Science, 2006, 313(5794):1785-7 (Highlighted in the same issue of Science and in Nature Reviews Cancer, November 2006). [* equal contribution].
- Buckstein, R., Kerbel, R.S., Shaked, Y., Nayar, R., Foden, C., Turner, R., Lee, CR., Taylor, D., Zhang, L., Man, S., Baruchel, S., Stempak, D., Bertolini, F. and Crump, M. High Dose Celecoxib and Metronomic ‘Low-Dose’ Cyclophosphamide is Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology NHL. Clinical Cancer Research, 2006, 12(17):5190-8.
- Bertolini, F., Shaked, Y., Mancuso, P. and Kerbel, R.S. The multifaceted circulating endothelial cell in cancer: from promiscuity to surrogate marker and target identification. Nature Reviews Cancer, 2006, 6:835–845 (Nov 2006, a featured article highlighted in the same issue of Nature Reviews Cancer).
- Shaked, Y., Bertolini, F., Man, S., Rogers, M.S. Cervi, D., Foutz, T., Rawn, K., Voskas, D., Dumont, D.J., Ben-David, Y., Lawler, J., Henkin, J, Huber, J., Hicklin, D.J., D’Amato, R.J. and Kerbel, R.S. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell, 2005, 7: 101-111.(Editorial in the same issue of Cancer Cell – 2005; 7 :3-4).
- Shaked, Y., Cervi, D., Neuman, M., Chen, L., Klement, G., Michaud, C.R., Haeri, M., Pak, B.J., Kerbel, R.S. and Ben-David, Y. The splenic microenvironment is a source of pro-angiogenesis / inflammatory mediators accelerating the expansion of murine erythroleukemic cells. Blood, 2005; 105:4500-7. (Cover of Blood).
- Shaked, Y.*, Emmenegger, U.*, Francia, G., Chen, L., Lee, C., Man, S., Paraghamian, A., Ben-David, Y. and Kerbel, R.S. Intermittent bolus dose combined with low-dose metronomic cyclophosphamide as an effective regimen for delaying relapse in both solid and hematologic malignancies. Cancer Research. 2005 ;65:7045-51. (Commentary in Cancer Research Highlights of the same issue and on the cover of the same issue) [* equal contribution].
- Shaked, Y., Emmenegger, U., Man, S., Cervi, D., Bertolini, F., Ben-David, Y. and Kerbel, R.S. The optimal biological dose of metronomic chemotherapy regimen is associated with maximum antiangiogenic activity. Blood 2005 ;105:4500-7. (Commentary in Nature Clinical Practice Oncology. 2005 2, 489).
- Francia, G., Green, S.K., Bocci, G., Man, S., Emmenegger, U., Ebos, J.M.L., Weinerman, A., Shaked, Y. and Kerbel, R.S. Downregulation of DNA mismatch repair proteins in human and murine tumor spheroids: Implications for multicellular resistance to alkylating agents. Molecular Cancer Therapeutics. 2005; 4:1484-94.
- Shaked, Y., Bocci, G., Munoz, R., Man, S., Ebos, J.M.L., Hicklin, D.J., Bertolini, F., D’Amato, R.J. and Kerbel, R.S. Review. Cellular and Molecular Surrogate Markers to Monitor Targeted and Non-Targeted Antiangiogenic Drug Activity and Determine Optimal Biologic Dose. Current Cancer Drug Target. 2005;5:551-9.
- Munoz, R., Shaked, Y., Bertolini, F., Emmenegger, U., Man, S., Kerbel, RS. Review. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast. 2005; 14:466-79.
- Pak, B.J., Lee, J., Thai, B.L., Fuchs, S.Y., Shaked, Y., Ronai, Z., Kerbel R.S. and Ben-David, Y. Radiation resistance of human melanoma analyzed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase. Oncogene. 2004; 23:30-38.
- Emmenegger, U., Man, S., Shaked, Y., Francia, G., Wong, J.W., Hicklin, D.J. and Kerbel, R.S. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Research. 2004; 64:3994-4000 (Cited in Cancer Research Highlights of the same issue).
- Hijazi, N., Shaked, Y., Rosenmann, H., Ben-Hur, T. and Gabizon, R. Copper binding to PrP(C) may inhibit prion disease propagation. Brain Research. 2003; 1993:192-200.
- Bertolini, F., Paul, S., Mancuso, P., Monestiroli, S., Gobbi, A., Shaked, Y. and Kerbel, R.S. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Research. 2003; 63:4342-6.
- Shaked, Y., Engelstein, R. and Gabizon, R. The binding of prion proteins to serum components is affected by detergent extraction conditions. Neurochemistry. 2002; 82:1-5.
- Shaked, Y., Hijazi, N. and Gabizon, R. Doppel and PrPC do not share the same membrane microenvironment. FEBS letter 2002; 530:85-8.
- Shaked, Y., Rosenmann, H., Hijazi, N., Halimi, M. and Gabizon, R. Copper binding to PrP Isoforms: A putative marker of their conformation and function. Virology. 2001; 75:7872-4.
- Shaked, G.M., Shaked, Y., Kariv, Z., Halimi, M., Avraham, I. and Gabizon, R. A protease resistant PrP isoform is present in urine of animals and humans affected with prion diseases. Biological Chemistry. 2001; 276:31479-82.
- Shaked, Y.*, Rosenmann, H.*, Talmor, G. and Gabizon, R. A C-terminal truncated PrP isoform is present in mature sperm. J. Biological Chemistry. 1999 ;274:32153-8.[* equal contribution].